NCT03402815View on ClinicalTrials.gov

Efficacy of Maraviroc in Modulating Atherosclerosis in HIV Patients.

PHASE4CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

January 1, 2015

Primary Completion Date

April 30, 2017

Study Completion Date

September 30, 2017

Conditions
HIV Infection With Other ConditionsCardiovascular Risk FactorAtherosclerosisInflammation
Interventions
DRUG

Maraviroc 300 mg

Patients were randomly allocated with an AB/BA cross over design to either maraviroc 300 mg/day to current ART for 24 weeks (A) or no additional treatment (B). At the end of the first 24-week period patients were switched to the alternative arm.

Trial Locations (1)

06126

Elisabetta Schiaroli, Perugia

All Listed Sponsors
lead

University Of Perugia

OTHER

NCT03402815 - Efficacy of Maraviroc in Modulating Atherosclerosis in HIV Patients. | Biotech Hunter | Biotech Hunter